Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

reated patients. The primary endpoint was ORR and secondary endpoints included CBR, TTP, DOR, OS and safety.
  • The 003-A1 study was an open-label, single-arm Phase 2b trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including bortezomib and either thalidomide or lenalidomide. Refractory disease was defined as less than or equal to a 25 percent response or progression during therapy, or progression within 60 days after completion of therapy.[ii]  The primary endpoint was ORR. Secondary endpoints included DOR, CBR, OS, TTP, PFS, and safety. 
  • The 007 study is an open-label Phase 1b/2 study. Results were reported from the dose-expansion phase of this ongoing study, which evaluated the safety and efficacy of a prolonged, 30-minute infusion of carfilzomib at a dose of 56mg/m(2). Endpoints included ORR, DOR, PFS, TTP, pharmacokinetics and safety.
  •  

    ASH Investor Teleconference
    Investigators and members of the Onyx management team will highlight data presented on carfilzomib featured at the 53rd ASH Annual Meeting and Exposition in San Diego, CA. The teleconference will begin at 10:00 a.m. PT on December 13, 2011.

    Interested parties may access the teleconference and the presentation that accompanies it on our website at:  

    http://www.onyx-pharm.com/investors/event-calendar

    or by dialing 847-585-4405 and using the passcode 31296220.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 31296220# later in the day.  The replay will be available on the Onyx website until December 27, 2011.

    Carfilzomib Development Program
    Carfilzomib is being studied in several clinical trials either as a single-agent or in combi
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... Nov. 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... retail drugstore chain in China ... announced the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of ... March 1999. Prior to Ms. Zhang,s appointment as the ...
    (Date:11/24/2014)... SEATTLE , Nov. 24, 2014 ... granted Breakthrough Therapy Designation to the company,s JCAR015 ... for the treatment of relapsed or refractory B-cell ... collaboration partner, Memorial Sloan Kettering Cancer Center, where ... "The FDA,s action is important news ...
    (Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
    Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
    ... (OMX Nordic: ACTI) presented,pre-clinical results for the ... League Against Rheumatism, <a target="_blank" href=,"http://www.eular.org/">www.eular.org ... data presented show that I-3D has a,significant ... model for rheumatoid arthritis (RA)", commented Sven,Andréasson, ...
    ... Percent Fewer RA Patients,Reported Job Loss When ... Alone, BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ ... most common causes of,disability in the Western ... arthritis (RA) patients treated with Abbott's HUMIRA(R),(adalimumab) ...
    Cached Medicine Technology:New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 2Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 3Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 4Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 5Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 6Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work,Productivity in Patients with Rheumatoid Arthritis 7
    (Date:11/26/2014)... Lenexa, Kansas (PRWEB) November 26, 2014 ... will showcase expanded capabilities at RSNA 2014 ... capture, access, manage and share diagnostic images, photos, ... Visitors to Perceptive’s booth #8107 will learn more ... including newly acquired technologies and partner initiatives – ...
    (Date:11/26/2014)... -- Youngsters who enter puberty early are at increased ... puberty was linked with a number of factors associated ... levels, according to the researchers. Early puberty was also ... and peers, and having friends who were prone to ... study found an association between early puberty and these ...
    (Date:11/26/2014)... (HealthDay News) -- The number of emergency department visits in ... to a record 136 million in 2011, according to the ... also showed that fewer people were going to ERs with ... needing medical care within two hours of arriving at the ... the research. Sixty percent of patients arrived at the ...
    (Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 ... may disrupt the makeup of bacteria in the digestive system, ... small new study suggests. The research doesn,t confirm ... ill, and study authors aren,t recommending that anyone stop taking ... be used at the lowest dose that provides adequate relief ...
    (Date:11/24/2014)... New York, NY (PRWEB) November 24, 2014 ... performance, the progressive world of fitness technology will take center ... Living in Digital Times at the 2015 International ... 5:00pm in the Venetian, Level 2, Bellini 2004). The bond ... industry evolves into being less about devices and more about ...
    Breaking Medicine News(10 mins):Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4
    ... Pharmacists Association (NCPA) is endorsing Rep. Walter Jones,(R-N.C.), ... who has been a powerful advocate for fixing ... is facing a,challenger in the North Carolina primary ... vice president and CEO of NCPA issued the ...
    ... examination by independent ... auditors, ... auditors as a result of its first Type,II SAS 70 compliance audit. ... a major U.S. accounting firm over a,period of five months. The audit ...
    ... in Spanish . , The removal through ... of the oesophagus can avoid complete extirpation of this ... at the University Hospital of Navarra for the last ... on Therapeutic Endoscopy in the Digestive System, organized by ...
    ... that possibly,could be adapted to prevent female mosquitoes ... only to malaria as the most,virulent mosquito-borne disease ... discovered 63 proteins that male mosquitoes,transfer to Aedes ... change the females, physiology and behavior, in particular,suppressing ...
    ... May 14, 2008, NEW YORK, April 10 ... Anniversary Celebration to,recognize a half century of achievements in ... to future endeavors., The Deafness Research Foundation is ... the US. DRF is dedicated to making a,lifetime of ...
    ... cost of ... ownership., ... uBid, which helps sellers and,manufacturers liquidate excess inventory, has chosen Microsoft ... Oracle,E-Business Suite enterprise resource planning system and its Siebel CRM,software. uBid, ...
    Cached Medicine News:Health News:GHX Achieves SAS 70 Compliance 2Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 2Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 3Health News:Removal of superficial tumors in esophagus by endoscopy can avoid extirpation of this part 4Health News:Mosquito mating mechanism could lead to new attack on dengue and yellow fever 2Health News:Deafness Research Foundation 50th Anniversary Celebration 2Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 2Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 3Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 4Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 5Health News:Asset-Recovery Leader Chooses Microsoft Dynamics AX and CRM Online 6
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: